Stage 4 Lung Cancer: 435 Real Stories

435 stories match lung cancer and stage 4. 243 of them mention chemotherapy.

Cancer Stories

Ashley, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Ashley's Patient Story

Patient Info: Ashley Smith, Female, Under 40 | Stage IV

Metastatic Site: pleura / malignant pleural fluid

As of November 2024, Ashley was living with Stage IV lung cancer and staying active, but the available source text did not state her treatment regimen or response status.

The Patient Story
OutcomeLiving With Cancer
Ashley, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley Vasallo, Female, Under 40 | Stage IV

Biomarkers: No actionable driver biomarker identified; rare fusion reported

Metastatic Site: spine, hip/bone, chest cavity

As of October 2024, Ashley reported clear labs and scans after radiation for small chest-cavity and hip lesions, with scans planned every 3 months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Metastatic Lung Cancer With Morphine-Induced Fever During Palliative Radiation

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: brain, bone

She remained on dacomitinib while receiving radiation for painful metastatic disease in 2022. After morphine was identified as the cause of recurrent fever and stopped, her symptoms resolved and she was discharged in satisfactory condition.

PubMed Central
OutcomeCare Ongoing
Florence, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Florence's Patient Story

Patient Info: Florence, Female, 40s | Stage IV

Metastatic Site: Brain

As of the September 2024 article update, Florence was living with metastatic lung cancer, traveling every 3 weeks for immunotherapy in a clinical trial, and reported less fatigue, more energy, and a return to sports and social life.

CancerConsult (FR)
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: stable disease on immunotherapy combination

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TP53, and MSH2 mutations; PD-L1 locally positive; Ki-67 20%; ALK negative. Markers otherwise supported lung cancer.

Metastatic Site: left atrium, right adrenal gland, skull; hilar and…

Stage IVB NSCLC remained clinically stable during carboplatin, pemetrexed, and tislelizumab, but treatment was stopped because of financial and psychological burden; later cancer status was not reported.

PubMed Central
OutcomeLiving With Cancer
Lindsay, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Lindsay's Patient Story

Patient Info: Lindsay Wagner, Female, 40s | Stage IV

Biomarkers: ALK-positive mutation / ALK rearrangement

Metastatic Site: brain; liver; bone; kidneys; lungs;…

As of September 2024, Lindsay was still on lorlatinib/Lorbrena with her lungs, liver, and kidneys described as stable, while isolated brain/bone areas were treated with radiation and monitored.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pulmonary large cell neuroendocrine cancer treated with airway procedures and pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR negative, ALK negative, ROS1 negative, TP53 negative, PD-L1 <1%, TMB 28.3 mut/Mb

Metastatic Site: bilateral lungs

Pembrolizumab-based treatment produced a complete remission, but multiple intrapulmonary metastases recurred in October 2021 after an 18-month progression-free interval. Further local airway treatment was performed and pembrolizumab continued.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small-cell lung cancer: complete response on durvalumab

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pericardial effusion; left supraclavicular lymph node

As of July 2024, she had clinical complete response after chemoimmunotherapy and chest radiation, improving immune-related bone changes, and ongoing durvalumab maintenance every 4 weeks.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer with brainstem metastasis: complete remission on chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: pons, right parietal lobe, brain

Stage IV NSCLC with pontine and right parietal brain metastases achieved complete remission after 2 years of chemotherapy with an anti-VEGF drug; the pontine lesion remained stable, and severe SRS-related central neuropathic pain improved after methadone escalation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR exon 19 deletion lung cancer: gefitinib after osimertinib toxicity

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion

As of August 2024, Stage IVB EGFR exon 19 deletion lung adenocarcinoma was being treated with gefitinib after osimertinib-induced grade 3 interstitial lung disease; ILD had not recurred, and low-dose prednisolone continued.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 EGFR-mutant lung cancer controlled on gefitinib after osimertinib intolerance

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 21 L858R mutation

As of August 2024, Stage IVB EGFR L858R lung adenocarcinoma was being treated with gefitinib after grade 3 osimertinib-induced interstitial lung disease; the cancer had not progressed when steroids were completed and ILD had not recurred on gefitinib.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: complete resection after splenectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: TTF-1-positive; Synaptophysin-positive; CD56-positive

Metastatic Site: spleen

No evidence of recurrence 1 year after open splenectomy/partial diaphragm resection and later R0 resection of the primary lung tumor for Stage IVB lung cancer with splenic metastasis; systemic therapy was refused.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutant lung adenocarcinoma transforming to small cell lung cancer during targeted therapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion, TP53 mutation, TMB 11 mut/Mb

Metastatic Site: cervical lymph nodes

At the last follow-up in February 2024, 32 months after diagnosis, she was alive and both the primary lung lesion and cervical lymph-node metastasis had decreased on combined chemotherapy, immunotherapy and targeted therapy.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Primary Lung Cancer That Spread to Both Breasts and the Adrenal Gland

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 negative; EGFR, ALK, ROS1, RET, MET exon 14, NTRK and BRAF wild type

Metastatic Site: both breasts, subcutaneous tissue, adrenal gland

After the lung origin was established, she was in good general condition and asymptomatic while first-line systemic therapy was being planned.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer: response to carboplatin, etoposide, and atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CD56-positive; synaptophysin-positive

Metastatic Site: right hilar/mediastinal disease, left adrenal gland,…

Extensive-stage small-cell lung cancer presenting with chronic intestinal pseudo-obstruction improved after 3 cycles of carboplatin, etoposide, and atezolizumab, with PET response and symptomatic improvement; longer-term durability was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: immunotherapy plus particle therapy halts progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 90%; high tumor mutational burden; PIK3CA ; TP53 mutation; MET mutation

Metastatic Site: left proximal femur

Stage IV oligometastatic NSCLC had good CT response to carboplatin, pemetrexed, and pembrolizumab, then no disease progression 6 months after PULSAR radiotherapy plus pembrolizumab; grade 2 pneumonitis improved with prednisone.

PubMed Central
OutcomeResponding Well